TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04065971: Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of 2LHERP® in Patients With Recurrent Orofacial Herpes Infections.

Sponsor: Labo'Life · Phase: PHASE4 · Area: INFECTIOUS_VACCINE · Target Enrollment: 140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,068,960

Rescue Site Savings

+$2,681,280

Unlock Full NCT04065971 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04065971 Rescue Dossier →